Prosecution Insights
Last updated: April 19, 2026
Application No. 18/220,874

IONIZABLE LIPIDS FOR NANOMATERIALS

Non-Final OA §103
Filed
Jul 12, 2023
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BEAM THERAPEUTICS INC.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
842 granted / 1237 resolved
+8.1% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
68 currently pending
Career history
1305
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.6%
-21.4% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is the first action on the merits. Election/Restrictions Applicant's election without traverse of Group (I) in the reply filed on February 27, 2026 is acknowledged. Group (I), drawn to compounds of formula (V), embraced by claims 1-4, 6, 8, 11-14, 16, 17, 19-22 and 24 was elected by Applicant. Applicant has not pointed to any errors in the Examiner’s analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected the following species, Example 4-7: PNG media_image1.png 110 456 media_image1.png Greyscale , and indicated claims 1, 16, 17, 19, 20 and 24 read on said species. The elected species was searched and not found. Thus, the search was expanded to all of Group (I). The species election is withdrawn. Claims 1, 14, 16, 17, 19, 20, 24-26, 34-36 and 38-41 are pending and claims 1, 16, 17, 19, 20 and 24 are under consideration. Claims 25, 26, 34-36 and 38-41 are withdrawn based on the restriction requirement. Specification The abstract of the disclosure is objected to because of the proper content of an abstract of the disclosure. In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., “The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral antidiabetics.” Exemplification of a species could be illustrative of members of the class. For processes, the type of reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary. Correction is required. See MPEP § 608.01(b). The objection may be overcome by adding the formula at the end of the abstract. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claim 24 is rejected under AIA 35 U.S.C. 103(a) as being unpatentable over Lokugamage et al. (Advanced Materials, 2019, 31, 1902251, 8 pages). The reference is cited on an IDS. The present application claims the following species in claim 24: PNG media_image2.png 109 292 media_image2.png Greyscale PNG media_image3.png 39 141 media_image3.png Greyscale . The reference teaches the following species: PNG media_image4.png 231 213 media_image4.png Greyscale , wherein R3 is PNG media_image5.png 64 118 media_image5.png Greyscale , see page 5 of 8. The only difference between the claimed compound and the cited species is the pyrrolidine ring on formula 1-A versus Applicant’s diethyl amine. The reference teaches the equivalency of these two groups in formula 11-A, see below: PNG media_image6.png 205 223 media_image6.png Greyscale . Thus, the two groups are considered alternatively useable. Therefore, claim 24 is obvious over Lokugamage et al. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 12, 2023
Application Filed
Mar 18, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600717
TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
2y 5m to grant Granted Apr 14, 2026
Patent 12583868
JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570656
PURINE COMPOUNDS FOR TREATING DISORDERS
2y 5m to grant Granted Mar 10, 2026
Patent 12552810
CRYSTALLINE FORMS OF CFTR MODULATORS
2y 5m to grant Granted Feb 17, 2026
Patent 12552804
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+32.2%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month